All In Biotech

Drug Trial Radar · NCT00158600

A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy and Pharmacokinetics of Myozyme in Patients With Late-Onset Pompe Disease.

Last checked: Nov 20, 2026Latest source record: Apr 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

90

Actual

Start

Sep 2005

Primary completion

Sep 2007

Study completion Sep 2007

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The overall objective is to evaluate the safety, efficacy, and pharmacokinetics (PK) of alglucosidase alfa treatment in patients with late-onset Pompe disease as compared to placebo.

Conditions

  • Pompe Disease (Late-onset)
  • Glycogen Storage Disease Type II (GSD-II)
  • Acid Maltase Deficiency Disease
  • Glycogenosis 2

Interventions

  • alglucosidase alfaBiological

    IV infusion of 20mg/kg; qow for 78 weeks.

  • PlaceboDrug

    Placebo Comparator; qow for 78 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summary of Patients Reporting Treatment-Emergent Adverse EventsTime frame: weeks 0-78
  2. Mean Distance Walked as Measured by Six-minute Walk Test (6MWT) at Weeks 0 and 78, and Mean Change From BaselineTime frame: weeks 0, 78
  3. Percent of Predicted Forced Vital Capacity (FVC)Time frame: weeks 0, 78
  4. Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Area Under the Curve (AUC)Time frame: weeks 0, 12 and 52
  5. Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Maximum Plasma Concentration(Cmax)Time frame: weeks 0, 12, 52
  6. Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Time to Maximum Plasma Concentration(Tmax)Time frame: weeks 0, 12, 52

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Tower Hematology Oncology Medical Group

    Beverly Hills, California

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Washington University Medical Center

    St Louis, Missouri

  • Mount Sinai School of Medicine

    New York, New York

  • University of Pittsburgh, Dept. of Neurology

    Pittsburgh, Pennsylvania

  • Groupe Hospitalier Pitie-Salpetriere

    Paris, France

  • Sophia Children's Hospital, Erasmus MC

    Rotterdam, Netherlands

  • Erasmus Medical Centre Rotterdam

    Rotterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.